Neutralizing GP41 antibodies and their use

US9783595B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Mark Connors · Bethesda, US
• Jinghe Huang · Bethesda, US
• Leo B. Laub · Richmond, US
• Peter Kwong · Washington, US
• Gary J. Nabel · Cambridge, US
• John Mascola · Rockville, US
• Baoshan Zhang · Bethesda, US
• Rebecca S. Rudicell · Cumberland, US
• Ivelin Georgiev · Nashville, US
• Yongping Yang · Potomac, US
• Jiang Zhu · San Ramon, US
• Gilad Ofek · Gaithersburg, US

Key dates

• Filing date: Aug 2, 2016
• Grant date: Oct 10, 2017
• Expiry date: Aug 2, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.